What MGUS means
MGUS stands for monoclonal gammopathy of undetermined significance. A clone of plasma cells produces a monoclonal protein, called the M protein, which is detected on serum protein electrophoresis or free light chain testing. By definition, the M protein is below 3 g/dL, clonal plasma cells in the marrow are below 10 percent, and there is no myeloma-defining event such as anaemia, kidney injury, bone lesions or hypercalcaemia.
MGUS is not cancer, but it is not simply normal either. It is a precursor state that needs periodic review. Most people with MGUS never develop myeloma, but the risk is higher than in the general population and persists for life.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Risk assessment and monitoring
Risk stratification uses the size and type of the M protein, the free light chain ratio and the presence of other abnormalities. An IgG M protein below 1.5 g/dL with a normal free light chain ratio carries a lower risk; a larger M protein, a non-IgG type or an abnormal ratio carries a higher risk. Smouldering myeloma, where the M protein is at least 3 g/dL or clonal cells are 10 to 60 percent without symptoms, needs closer follow-up.
Monitoring usually includes a blood count, calcium, creatinine, M protein and free light chain tests, with urine studies where relevant. The interval depends on the risk and stability of the findings. Imaging or a bone marrow biopsy is arranged when symptoms, laboratory change or high-risk features suggest progression.
| Finding | What it means |
|---|---|
| M protein below 3 g/dL | Compatible with MGUS when other criteria are met |
| Clonal plasma cells below 10 percent | Supports MGUS rather than smouldering or active myeloma |
| No CRAB or SLiM features | No myeloma-defining organ damage or biomarkers |
| Rising M protein or abnormal free light chain ratio | Higher risk; closer monitoring or further tests |
Symptoms and when to investigate further
MGUS itself does not cause tiredness, bone pain or neuropathy in most people. Those symptoms should not automatically be attributed to MGUS. New back or bone pain, unexplained anaemia, high calcium, kidney problems, recurrent infection, numbness or protein in the urine need evaluation for myeloma, AL amyloidosis or another cause.
There is no treatment that is proven to prevent progression in standard-risk MGUS, so the priority is avoiding both undertreatment and overtreatment. Treatment is started only when active myeloma or a related disorder is diagnosed. Clinical trials are considered in selected high-risk settings.
Access and booking
Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital. Appointments are arranged at the Durbar Marg clinic or through the respective hospital or cancer centre. Bring all blood counts, blood film, marrow, flow cytometry and molecular reports.